Table 1 Baseline demographic characteristics of patients enrolled in the ALZ2002 (safety set)
Baseline characteristics | Treatment group at start ALZ2002 | |||
|---|---|---|---|---|
Placebo | 10 mg | 50 mg | Total | |
N | 39 | 37 | 38 | 114 |
Sex, men,n(%) | 16 (41.0) | 18 (48.6) | 20 (52.6) | 54 (47.4) |
Age, years | ||||
Mean (SD) | 70.3 (5.38) | 70.9 (6.58) | 68.1 (8.55) | 69.8 (6.99) |
Range | 59; 80 | 52; 81 | 50; 82 | 50; 82 |
Race | ||||
White,n(%) | 37 (94.9) | 36 (97.3%) | 38 (100.0) | 111 (97.4) |
Other,n(%) | 2 (5.1) | 1 (2.7) | 0 (0.0) | 3 (2.6) |
APOEε4 carrier status known,n | 27 | 30 | 22 | 79 |
Yes,n(%) | 17 (63.0) | 18 (60.0) | 10 (45.5) | 45 (57.0) |
No,n(%) | 10 (37.0) | 12 (40.0) | 11 (50.0) | 33 (41.8) |
Preclinical AD, CDR = 0,n(%) | 7 (17.9) | 8 (21.6) | 9 (23.7) | 24 (21.1) |
MCI due to AD, CDR = 0.5,n(%) | 32 (82.1) | 29 (78.4) | 29 (76.3) | 90 (78.9) |